2016
DOI: 10.1200/jco.2016.66.4466
|View full text |Cite
|
Sign up to set email alerts
|

Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study

Abstract: This phase II study demonstrates that BeGEV is an effective salvage regimen able to induce CR in a high proportion of patients with relapsed or refractory HL before ASCT. These data provide a strong rationale for further development of the BeGEV regimen.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

7
88
2
6

Year Published

2018
2018
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 87 publications
(103 citation statements)
references
References 29 publications
7
88
2
6
Order By: Relevance
“…Although the ORR of 83% was superior to that reported in the current study, this population was limited to patients who had received only 1 prior line of therapy and who had not undergone ASCT. The 2‐year PFS and OS rates after ASCT in the study by Santoro et al were >80%, which is comparable to the current study findings in the limited cohort of patients who completed ASCT. We also recognized that both Santoro et al and the current study used response criteria that were published prior to the currently used Lugano classification.…”
Section: Discussionsupporting
confidence: 89%
See 3 more Smart Citations
“…Although the ORR of 83% was superior to that reported in the current study, this population was limited to patients who had received only 1 prior line of therapy and who had not undergone ASCT. The 2‐year PFS and OS rates after ASCT in the study by Santoro et al were >80%, which is comparable to the current study findings in the limited cohort of patients who completed ASCT. We also recognized that both Santoro et al and the current study used response criteria that were published prior to the currently used Lugano classification.…”
Section: Discussionsupporting
confidence: 89%
“…Santoro et al published the results of a phase 2 study of gemcitabine, bendamustine, and vinorelbine as pretransplantation salvage in 59 patients . Although the ORR of 83% was superior to that reported in the current study, this population was limited to patients who had received only 1 prior line of therapy and who had not undergone ASCT.…”
Section: Discussioncontrasting
confidence: 53%
See 2 more Smart Citations
“…Recently, the combination of bendamustine, gemcitabine and vinorelbine (BeGeV regimen) has been successfully tested in 59 patients with relapsed or refractory HL (46% with primary refractory disease and 37% with a CR lasting less than 1 year) in a phase 2 trial (Santoro et al , ). After 4 cycles of treatment, 43 patients (73%) achieved a CR and 6 patients (10%) a partial response (PR), with grade 3–4 thrombocytopenia and neutropenia experienced in 13·5% of patients each, thus enabling safe outpatient administration.…”
Section: The Pre‐autologous Setting: Boosting Responses Before Transpmentioning
confidence: 99%